Haroun Gajraj: Polidocanol or STS – Choosing the Right Sclerosant
Haroun Gajraj, Phlebologist and Board Member of the British Association of Sclerotherapists, shared a post on LinkedIn:
“The Best Sclerosant for Leg Spider Veins: Polidocanol or STS?
Every phlebologist has this debate at some point.
Here’s my opinion: neither is proven to be categorically better.
The trial everyone points to (EASI) compared one specific polidocanol regimen against one specific STS regimen, not the drugs at equivalent strength.
Patients were more satisfied with the polidocanol arm, but that’s a regimen finding, not proof of superiority.
The older comparative studies don’t settle it either, and the lab data on platelets and clotting is useful mechanistic background, not a real-world complication-rate comparison between the two.
So how do you actually choose?
Patient comfort, prior individual response, and your own consistent technique are all important deciding factors, on the evidence we currently have.
What sclerosant do you use?
I look at the evidence and I spell it all out in my latest blog post …”
Other posts featuring Haroun Gajraj on Hemostasis Today.
-
Oct 28, 2026, 14:56Elizabeth Shirley: COVID-19 Vaccines, Spike Protein and Nitric Oxide Bioavailability
-
Oct 28, 2026, 14:39David Ledger: Anticoagulation Advances as Factor XIa Inhibition Reaches a New Milestone
-
Oct 28, 2026, 14:37Advancing Liver Health in Haemophilia Care – EAHAD
-
Oct 28, 2026, 14:34The Changing Landscape of Anticoagulant Therapy – ISTH
-
Oct 28, 2026, 14:17Clusterin Regulates von Willebrand Factor Multimer Stability Through ADAMTS13 Inhibition
-
Oct 28, 2026, 14:14Mina Jarrahi: Platelet-Rich Fibrin for Periodontal Regeneration
-
Oct 28, 2026, 14:06Mohammed Alo: A Stent Treats the Blockage, Not the Underlying Disease
-
Oct 28, 2026, 13:58Vladimir Lemaire: When Blood Clots Affect Elite Athletes
-
Oct 28, 2026, 13:27M. Alejandro Mosso-Pani: Dengue in Florida – Why Platelet Function Matters